Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial-Reference-Cited by-全球学者库

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Published:2012-03 Issue:3 Volume:13 Page:239-246
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rosell Rafael,Carcereny Enric,Gervais Radj,Vergnenegre Alain,Massuti Bartomeu,Felip Enriqueta,Palmero Ramon,Garcia-Gomez Ramon,Pallares Cinta,Sanchez Jose Miguel,Porta Rut,Cobo Manuel,Garrido Pilar,Longo Flavia,Moran Teresa,Insa Amelia,De Marinis Filippo,Corre Romain,Bover Isabel,Illiano Alfonso,Dansin Eric,de Castro Javier,Milella Michele,Reguart Noemi,Altavilla Giuseppe,Jimenez Ulpiano,Provencio Mariano,Moreno Miguel Angel,Terrasa Josefa,Muñoz-Langa Jose,Valdivia Javier,Isla Dolores,Domine Manuel,Molinier Olivier,Mazieres Julien,Baize Nathalie,Garcia-Campelo Rosario,Robinet Gilles,Rodriguez-Abreu Delvys,Lopez-Vivanco Guillermo,Gebbia Vittorio,Ferrera-Delgado Lioba,Bombaron Pierre,Bernabe Reyes,Bearz Alessandra,Artal Angel,Cortesi Enrico,Rolfo Christian,Sanchez-Ronco Maria,Drozdowskyj Ana,Queralt Cristina,de Aguirre Itziar,Ramirez Jose Luis,Sanchez Jose Javier,Molina Miguel Angel,Taron Miquel,Paz-Ares Luis

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci USA,2004

5. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies;Ji;Cancer Cell,2006

Cited by 4618 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drivers of cancer metastasis – Arise early and remain present;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-03

2. Pantoprazole enhances osimertinib activity by inhibiting autophagy in NSCLC cells and tumor xenografts;2024-02-06

3. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs;Frontiers in Oncology;2024-02-05

4. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

5. HSP90: A promising target for NSCLC treatments;European Journal of Pharmacology;2024-02